Effect of Cucumis Melo L seeds on patients with benign prostatic hypertrophy

Comparison the effect of Cucumis Melo L seeds oral product and Tamsulosin with Tamsulosin and placebo in reducing the symptoms of patients with benign prostatic hypertrophy.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180712040446N3

Enrollment

Registered

2022-03-07

Start date

2022-03-21

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Benign Prostatic Hypertrophy. Condition 2: Lower Urinary Tract Symptoms. Enlarged prostate with lower urinary tract symptoms Enlarged prostate with lower urinary tract symptoms

Interventions

Intervention 1: Intervention group: Will received Tamsulosin (0.4 mg per night, 1 piece) with Cucumis melo L seeds 500 mg oral capsule three times daily after each meal for up to 6 weeks. The medicin

Eligibility

Sex/Gender

Male

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: All patients aged 45 to 75 years with BPH who include at least one of the following: International Score of Prostate Symptoms (IPSS) over 13 at the time of screening PSA higher than 3 ng / ml. Prostate volume greater than 30 mm detected by ultrasound Patients who are able and willing to sign a written consent.

Exclusion criteria

Exclusion criteria: Surgery, infection, lower urinary tract disease (bladder stones, neurogenic bladder, bladder malignancy, urethral stricture, hematuria Gross) Diabetes, Heart disease (heart failure, MI, unstable angina), Hepato-renal disease Use of drugs affecting the bladder and prostate (anticholinergics, sympathomimetics, antidepressants) Patients who are unable to use oral medication. Participate in concurrent drug intervention. Allergy to medicinal plants.

Design outcomes

Primary

Measure	Time frame
??????? ?????? ??? ?????? ????? ???????. Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: Questionnaire.;Q max. Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: Euroflowmetry.;Prostate volume. Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: Sonography.	—

Secondary

Measure	Time frame
Prostate specific antigen (PSA). Timepoint: Before the intervention and 2 weeks after the intervention. Method of measurement: ELISA test.;Drug side effects. Timepoint: During the study and two weeks after the study. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Pejman Shadpour

Iran University of Medical Sciences

pshadpour@gmail.com+98 21 81161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026